期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 23, 期 16, 页码 2995-3002出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v23.i16.2995
关键词
Inflammatory bowel disease; Corticosteroids; 5-aminosalicylates; Ulcerative colitis
资金
- Schering-Plough
- AbbVie
- Celltrion
- Pfizer
- Ferring
- Janssen
- Takeda
- AENORASIS
- UCB
- Bingham Chair in Gastroenterology
- Abbvie Canada
- Janssen Canada
- Shire Canada
- Takeda Canada
- Sandoz
- Gutsy Foundation
- NMHRC
- Takeda Pharmaceuticals
- Dr Falk
- Merck Sharp
- Dohme Ltd
- Astrazeneca
- Gilead
- Xian-Janssen
- Beaufour Ipsen (Tianjin China)
- Rafa Ltd
- MSD
AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates (5ASA) with corticosteroids (CS) versus corticosteroids alone for patients with active ulcerative colitis (UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received (52.6% response rate). Of 340 eligible respondents, 221 (65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108 (32%) would stop the 5ASA (P < 0.001), and 11 (3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340 (41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most (94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据